Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -39.67% is 15% below its 3-year average of -34.56%, around the middle of its 3-year range (-50.01%–-17.95%).
75.41% below its 12-month average of -22.62%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.58%.
RETURN ON ASSETS (ROA)
-39.67%
RETURN ON ASSETS (ROA) AVG TTM
-22.62%
RETURN ON ASSETS (ROA) AVG 3Y
-34.56%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-75.41%
CURRENT VS 3Y AVG
-14.79%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.55%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-68.41%
vs the sector median at left
CeriBell, Inc.
Market Cap
$943.26M
Return on Assets (ROA)
-39.67%
TTM Avg
-22.62%
3Y Avg
-34.56%
5Y Avg
N/A
Market Cap
$922.50M
Return on Assets (ROA)
55.85%
TTM Avg
-44.25%
3Y Avg
-43.62%
5Y Avg
-43.05%
Market Cap
$915.95M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
Market Cap
$903.13M
Return on Assets (ROA)
-22.62%
TTM Avg
-55.95%
3Y Avg
-57.94%
5Y Avg
-46.38%
Market Cap
$985.79M
Return on Assets (ROA)
-56.27%
TTM Avg
-37.98%
3Y Avg
-21.94%
5Y Avg
-21.15%
Market Cap
$989.05M
Return on Assets (ROA)
-13.12%
TTM Avg
-18.77%
3Y Avg
-18.48%
5Y Avg
-18.48%
Market Cap
$867.60M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$852.55M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $943.26M | -39.67% | -22.62% | -34.56% | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 55.85% | -44.25% | -43.62% | -43.05% |
| Bioventus Inc. (BVS)vs › | $915.95M | 8.09% | -0.64% | -8.03% | -4.54% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | -22.62% | -55.95% | -57.94% | -46.38% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | -56.27% | -37.98% | -21.94% | -21.15% |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | -13.12% | -18.77% | -18.48% | -18.48% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -23.15% | -12.59% | -25.36% | -32.38% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -24.96% | -29.43% | -70.30% | -70.30% |
| Alumis Inc. (ALMS)vs › | $844.28M | -78.30% | -72.68% | -105.45% | -105.45% |
ROA
-39.7%
ROE
-51.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -27.28% |
| 2024-12-31 | -17.95% |
| 2023-12-31 | -50.01% |
| 2022-12-31 | -42.99% |
